IMMUNOTHERAPY PUBLICATIONS & ABSTRACTS
Immunotherapy Data
Evidence / Immunotherapy
Neoadjuvant CT & Immunotherapy in HR+/HER2-negative breast cancer
Journal of Clinical Oncology, April 9, 2024 Presenter: Rios-Hoyo et al.
Read MoreIMPRINT-TN: Triple-Negative Breast Cancer, Unlikely to Respond to Immunotherapy
2024 European Breast Cancer Conference (EBCC) (Abstract 2LBA) Presenter: Wolf et al.
Read MoreImPrint immune signature in 10,000 early stage breast cancer patients from FLEX Study
SABCS 2022, Poster ID: PD9-08 Authors: Brufsky et al.
Read MoreI-SPY2: ImPrint immune signature identifies ESBC patients who benefit from PD1 checkpoint inhibition
ASCO 2022, Poster #514 Authors: Kuilman et al.
Read MoreDurvalumab + olaparib + paclitaxel in High-risk HER2-negative ESBC: I-SPY2 trial results
I-SPY2 Trial, Cancer Cell 39, 989–998, 2021 Authors: Pusztai et al.
Read More
